Treatments for Platinum-Resistant Ovarian Cancer


Immunotherapy Combinations

In February 2026, the U.S. Food and Drug Administration (FDA) approved a new treatment for platinum-resistant ovarian cancer that combines immunotherapy and chemotherapy infusions: pembrolizumab (Keytruda) plus weekly paclitaxel (Taxol), with or without bevacizumab (Avastin).



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top